Tandem Diabetes Care (TNDM) Gross Margin (2013 - 2026)
Tandem Diabetes Care's (TNDM) quarterly Gross Margin came in at 56.87% in Q2 2026, up 458.0% on a YoY basis from 10.19% in Q2 2025, and up 2.79% quarter-over-quarter from 55.33% in Q1 2026.
Powered by 
Analysis
Tandem Diabetes Care (TNDM) Gross Margin (2013 - 2026) Analysis & Trends
Tandem Diabetes Care (TNDM) has reported Gross Margin for 14 consecutive years, with 56.87% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Gross Margin rose 458.0% year-over-year to 56.87%; the trailing twelve-month figure through Jun 2026 stood at 56.01% (up 347.0% YoY), and the FY2025 full-year result was 53.81%, up 174.0% from the prior year.
- Gross Margin grew to 56.87% in Q2 2026 per TNDM's latest filing, from 55.33% in the prior quarter.
- Across five years, Gross Margin topped out at 57.67% in Q4 2025 and bottomed at 47.41% in Q4 2023.
- Historically, Gross Margin has averaged 52.02% across 5 years, with a median of 51.44% in 2022.
- The sharpest annual moves came in 2023 and 2024: Gross Margin plunged 498 bps in 2023, then soared 830 bps in 2024.
- Over 5 years, Gross Margin stood at 52.39% in 2022, then declined by 10 bps to 47.41% in 2023, then advanced by 18 bps to 55.71% in 2024, then climbed by 4 bps to 57.67% in 2025, then declined by 1 bps to 56.87% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 56.87%, 55.33%, and 57.67% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.78 Bn | 175.17 Bn | 7.27 Bn | 57.71% |
| 2 | Intuitive Surgical | 127.04 Bn | 121.82 Bn | 1.96 Bn | 67.78% |
| 3 | Medtronic | 117.04 Bn | 108.22 Bn | 6.34 Bn | 64.99% |
| 4 | Stryker | 103.86 Bn | 100.38 Bn | 4.50 Bn | 68.27% |
| 5 | Boston Scientific | 63.50 Bn | 62.96 Bn | 3.85 Bn | 70.71% |
| 6 | Edwards Lifesciences | 49.74 Bn | 45.49 Bn | 1.35 Bn | 77.46% |
| 7 | Alcon | 32.99 Bn | 31.53 Bn | 1.68 Bn | 60.21% |
| 8 | Dexcom | 32.12 Bn | 30.17 Bn | 830.00 Mn | 63.44% |
| 9 | Steris | 20.69 Bn | 20.21 Bn | 684.20 Mn | 45.84% |
| 10 | Tandem Diabetes Care | 1.27 Bn | 811.05 Mn | 144.78 Mn | 56.87% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 56.87% |
| Mar 31, 2026 | 55.33% |
| Dec 31, 2025 | 57.67% |
| Sep 30, 2025 | 53.88% |
| Jun 30, 2025 | 52.29% |
| Mar 31, 2025 | 50.51% |
| Dec 31, 2024 | 55.71% |
| Sep 30, 2024 | 51.09% |
| Jun 30, 2024 | 50.83% |
| Mar 31, 2024 | 49.39% |
| Dec 31, 2023 | 47.41% |
| Sep 30, 2023 | 48.35% |
| Jun 30, 2023 | 51.93% |
| Mar 31, 2023 | 48.95% |
| Dec 31, 2022 | 52.39% |
| Sep 30, 2022 | 51.05% |
| Jun 30, 2022 | 50.91% |
| Mar 31, 2022 | 51.78% |
| Dec 31, 2021 | 54.16% |
| Sep 30, 2021 | 53.86% |